These therapies need to be used carefully because excessive blocking of the PD-1/PD-L1 axis can result in autoimmune conditions, which is one of the side effects of anti-PD-1/PD-L1 ICBs [60]. This evidence concerns the gene PDCD1 and Autoimmunity.